Integrated Products
Chemistry Products
Immunodiagnostic Products
Lab Automation
Menu of assays
Data management
Integrated Product Portfolio
Assay Menu and Lab Management Solutions
Chemistry and immunodiagnostics
Transfusion Medicine
Support
For more than 80 years, Ortho Clinical Diagnostics has been guided by its purpose: to improve and save lives with diagnostics.
QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.
Waterless Technology has a huge impact for the clinical laboratory
The Power of B•R•A•H•M•S with the Difference that only VITROS® can Deliver
Multi-test technology allows labs to run two frequently ordered tests simultaneously on one slide.
Helps more rapidly and accurately identify patients suffering from a heart attack.
Enables powerful data intelligence, operational improvements and other enhancements in the lab.
Honor by PM360 recognizes impact in the health care industry through innovation, social responsibility and talent development.
Ortho’s VITROS® NEPHROCHECK® Test recognized with a gold-level Edison Award™ in the Best New Product Awards™ category
Ortho Clinical Diagnostics receives CE Mark approval for ORTHO CONNECT™ V2.0 Middleware Solution
Ortho receives an Edison Award™ for Global Product Innovation, for its ORTHO VISION® Platform of fully automated analyzers, which test blood for compatibility before it is used in transfusions
The U.S. FDA clears ORTHO VISION® Max Analyzer for High-Volume Transfusion Medicine Labs, making it commercially available in the U.S.
The U.S. FDA clears VITROS® Automation Solutions for use with Ortho’s VITROS® Chemistry, Immunodiagnostics and Integrated Systems, allowing U.S. clinical laboratories to improve results throughout diagnostic testing
Ortho Clinical Diagnostics receives CE Mark approval for its Immunodiagnostic HIV Combo Test, making it commercially available in those countries that accept CE Mark
Ortho Clinical Diagnostics receives 510(k) clearance for ORTHO VISION® Analyzer, making it commercially available in the United States. ORTHO VISION® Analyzer automates the full range of immunohematology testing and helps improve the safety of blood transfusions by reducing the lab's reliance on manual methods
VITROS® Automation Solutions released in EU and non-regulated markets
Ortho Clinical Diagnostics Receives CE Mark Clearance for ORTHO VISION® Max Analyzer for High-Volume Transfusion Medicine Labs, becoming commercially available in Europe and Japan
The Carlyle Group acquires Ortho Clinical Diagnostics from Johnson & Johnson
Ortho Clinical Diagnostics receives CE Mark for ORTHO VISION® Analyzer, making it commercially available in Europe, Japan and Australia
Ortho Clinical Diagnostics launches ORTHO™ Workstation, a next-generation semi-automated blood typing system
Ortho Clinical Diagnostics launches the VITROS® 4600 Chemistry System for mid- to high-volume laboratories
Ortho Clinical Diagnostics launches the VITROS® 5600 Integrated System, which integrates clinical chemistry and immunoassay testing, and the VITROS® 3600 Immunodiagnostic System
Ortho Clinical Diagnostics launches the first FDA-licensed test to screen blood donations for exposure to Chagas' disease
Ortho Clinical Diagnostics launches the VITROS® 350 Chemistry System
Ortho Clinical Diagnostics launches the VITROS® 5, 1 FS Chemistry System, raising industry standards for ease-of-use, integrity of results, and operational efficiency
Ortho Clinical Diagnostics launches the VITROS® ECiQ Immunodiagnostic System and the ORTHO AutoVue® Innova System
Ortho Clinical Diagnostics acquires Micro Typing Systems of Pompano Beach, Florida, the manufacturer of the ID-Micro Typing System™ (ID-MTS) used in hospitals and donor centers to help to ensure safe and effective blood transfusions
Ortho Clinical Diagnostics becomes the first diagnostic company to receive US FDA approval for automated random access hepatitis tests, on the VITROS® ECi Immunodiagnostic System (for diagnostic use only; not for blood screening)
Ortho Clinical Diagnostics develops Ortho trak-C™, the world’s first branded “Total HCV Core Antigen” test designed to provide reliable measures of HCV viremia
Ortho Clinical Diagnostics releases the HCV Core Antigen ELISA Test System—the first test commercially available for the direct detection in blood and plasma of HCV core antigen, a marker of early infection in hepatitis C–infected individuals
Ortho Clinical Diagnostics becomes one of the first diagnostic industry suppliers to offer contracted implementation services that can significantly reduce clinical laboratory costs through operational efficiencies and streamlined processes
Ortho Clinical Diagnostics introduces the ORTHO AutoVue® System, the first fully automated blood banking system in Europe
Ortho Clinical Diagnostics is formed from the merger of two Johnson & Johnson companies: Ortho Diagnostic Systems, a worldwide leader in transfusion medicine reagents and instrument systems, and Johnson & Johnson Clinical Diagnostics (formerly a division of Eastman Kodak Co.), a worldwide leader in clinical laboratory systems
Ortho Products introduces the most advanced immunodiagnostic system available in the industry, the VITROS® ECi Immunodiagnostic System
Ortho Clinical Diagnostics introduces the Ortho Summit™ System, the first fully automated blood and plasma screening system available in the US
Ortho Products introduces the first test for the detection of antibodies to hepatitis C
Ortho Products introduces patented thin-film dry slide technology, once again revolutionizing the field of diagnostics by providing clinical professionals with the means to receive high-quality results quickly, cleanly, and economically
Ortho Products develops the first blood bank anti-D test for the clinical market. This is a revolutionary advance in the burgeoning blood banking industry.
Dr. Philip Levine, a pioneer in the field of hematology, joins Ortho Products to continue his breakthrough research into the mechanics of the Rh system in human blood. This marks the beginning of the company's commitment to diagnostic medicine. Among Dr. Levine's many contributions is research that leads to the development of Rh immune globulin to protect Rh-negative women against isoimmunization, saving the lives of thousands of babies.
Ortho Products, Inc., is formed in Linden, New Jersey, as a division of Johnson & Johnson
Enjoy unlimited access to the very best insights across the diagnostic community including industry reports and regular webinars from thought leaders.
Sign up for Free!